About
This fixed-dose combination medication brings together a dipeptidyl peptidase-4 (DPP-4) inhibitor and dapagliflozin, an SGLT2 inhibitor, to provide comprehensive glycemic control for adults with type 2 diabetes. The DPP-4 inhibitor enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner by preserving incretin hormones. Dapagliflozin works independently of insulin by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, leading to increased urinary glucose excretion and a reduction in blood glucose levels. This dual action addresses different pathophysiological pathways of type 2 diabetes, offering improved HbA1c reduction, potential weight loss, and blood pressure reduction, making it a valuable option for patients requiring multi-faceted treatment.
Uses
- Treatment of type 2 diabetes mellitus.
- Improvement of glycemic control.
- Reduction of cardiovascular risk in certain patients.
- As an adjunct to diet and exercise.
Directions For Use
Take orally once daily in the morning, with or without food, as prescribed by your healthcare provider.
Benefits
- Significant HbA1c reduction.
- Insulin-independent glucose lowering (Dapagliflozin).
- Potential for weight loss.
- May lower blood pressure.
- Reduced risk of cardiovascular events (Dapagliflozin).
- Convenient once-daily dosing.
Side Effects
- Urinary tract infections
- Genital mycotic infections
- Increased urination
- Nausea
- Headache
- Back pain
- Dizziness
- Hypoglycemia (especially with other antidiabetics)
- Dehydration
- Ketoacidosis (rare)
- Fournier's gangrene (very rare)
- Hypotension
Safety Measures
- Alcohol - Moderate alcohol intake is generally acceptable, but excessive consumption may increase the risk of dehydration or hypoglycemia, especially if combined with other antidiabetic drugs.
- Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal kidney development. Consult your doctor.
- Breastfeeding - It is unknown if the DPP-4 inhibitor or dapagliflozin are excreted in human milk. A decision should be made whether to discontinue nursing or the drug.
- Liver - No dose adjustment is typically needed for mild to moderate hepatic impairment. Use with caution in severe impairment.
- Kidney - Not recommended for patients with severe renal impairment (eGFR <25 mL/min/1.73m²). Efficacy is reduced with declining renal function.
- Lung - No specific contraindications related to lung conditions. Ensure adequate hydration, especially in patients with respiratory illness.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!